瑞士，星期五，2020年2月14日 11:40 AM 欧洲中部时间
Demiurge致力于利用AI为2019新型冠状病毒（COVID-19）筛选新型候选治疗药物。基于Demiurge开发的精确广谱病毒学模型，我们对已发表的COVID-19研究数据进行了深入的分析。
我们发现磷酸肌醇3-激酶（phosphoinositide 3-kinase）抑制剂（PI3K抑制剂）有望成为选择性针对COVID-19的高效和安全的新型候选治疗药物，尽管PI3K抑制剂可能对SARS冠状病毒或MERS冠状病毒并不具有同样的有效性和安全性。
PI3K抑制剂的作用机制不但已经被科学界广泛研究，而且已经被医药企业积极用于开发多种癌症的创新疗法。一部分PI3K抑制剂（例如 Idelalisib、Copanlisib、 Duvelisib、 Alpelisib）已获批上市，适用于各种淋巴癌的治疗。 更多的PI3K抑制剂已进入到三期临床试验（例如Taselisib、Buparlisib、Umbralisib、Voxtalisib等），适用于更广泛癌症类型的治疗。
PI3K抑制剂的抗病毒潜力在医学文献中已有所涉及，但尚未得到充分的重视和开发。Demiurge在建立肿瘤学领域和病毒学领域的交叉疾病模型的过程中，通过利用机器智能和人类智能的互补优势，有效解决了数据遗漏和数据错标等问题，进而基于COVID-19的流行病学特征、临床特征、和生物学特性，发现PI3K抑制剂有望成为选择性针对COVID-19的高效和安全的新型候选治疗药物。
在慢性病领域，药物专利的排他性和药物销售的独家性，有效激励医药企业完成漫长而昂贵的新药开发，最终普惠大众。但是在流行病领域，时间是最为稀缺的要素。公众对治疗药物需求的紧迫性和药企对治疗药物供给的独家性通常在时间上是难以兼顾的。然而我们相信，在对抗流行病对生命的威胁时，深耕于医药事业的企业和个人都会将公众福祉放在首位。争分夺秒，阻击病毒。
因此，面对COVID-19, Demiurge决定第一时间向公众公布我们发现的新型候选治疗药物PI3K抑制剂，放弃平常时期申请专利保护、独家权益合作等环节。以期能尽吾之所长，协同业界上下游，尽快开展PI3K抑制剂的三期临床试验。
关于Demiurge Technologies AG
Demiurge Technologies是一家以研究为基础的AI技术与生物医药公司，致力于将公开的海量生命科学数据转换为精确疾病模型。Demiurge创新地建立了利用全球医药三期临床试验结果预测的准确性来验证并改良精准疾病模型的科学进化闭环。同时Demiurge 致力于将精准疾病模型发现的创新药物进行商业化开发。 Demiurge于2016年开始运营，总部位于瑞士。
AI已成为一种新型强大的技术方法，它可以帮助人类更深入地了解疾病和更快地发现药物。但AI必须经过严格的测试，在公众的监督下证明其价值。Demiurge已经完成了90多个三期临床试验结果的预测，实现了大于80%的准确率。同时，我们在推特（Twitter）上邀请公众参与见证我们对正在进行中的全球新药三期临床试验结果的预测（@DemiurgeTech）。
因此，我们在这里基于AI提出了PI3K抑制剂做为COVID-19的新型候选药物的科学假设，并公开邀请世界各地通过随机对照临床试验的方式，验证PI3K抑制剂是否可以安全有效地治疗COVID-19。Demiurge敦促大众在任何相关临床试验结果公布之前，不应将PI3K抑制剂等同于COVID-19的治疗药物擅自使用。
Disclaimers
This material is intended for information purposes only and is provided without any warranty of any kind, either expressed or implied. These statements are not guarantees of future performance, condition or results. Figures and graphs in this presentation are for illustration only and are may not match the actual scale. This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’,‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees. Demiurge Technologies AG (“Demiurge”) undertakes no duty or obligation to publicly update or revise the forward-looking statements or other information contained in this presentation. You should not view information related to the past performance of Demiurge and its affiliates or information about the market, as indicative of future results, the achievement of which cannot be assured. While some information used in this document may have been obtained from various published and unpublished sources considered to be reliable, Demiurge neither guarantees its accuracy or completeness nor accepts liability for any direct or consequential losses arising from its use. Amounts and percentages may reflect rounding adjustments and consequently totals may not appear to sum. None of the information in this presentation does, by itself, constitute an offering or an offering circular according to Article 652a of the Swiss Code of Obligations and is subject to change without notice. Any offer or solicitation with respect to any securities that may be issued by Demiurge will be made only by means of definitive offering memoranda or prospectus, which will be provided to prospective investors and will contain material information that is not set forth herein, including risk factors relating to any such investment. Before making an investment, you must obtain and carefully read all information needed to evaluate the investment, including, but not limited to the documents providing important disclosures regarding risks, fees and expenses. An investment in Demiurge may be volatile and can suffer from adverse or unexpected market moves or other adverse events. Investors may suffer the loss of their entire investment. An investment in Demiurge will be discrete from an investment in any funds or other investment programs managed by Demiurge and the results or performance of such other investment programs is not indicative of the results or performance that will be achieved by Demiurge or such investment programs.
* 中英文通告的最终解释以英文为准
